Zoster vaccine recommendations: the importance of using a clinically valid correlate of protection
- PMID: 21524565
- PMCID: PMC5381800
- DOI: 10.1016/j.vaccine.2011.04.019
Zoster vaccine recommendations: the importance of using a clinically valid correlate of protection
Comment in
-
Perspective of the U.S. Food and Drug Administration on concomitant administration of Zostavax and Pneumovax.Vaccine. 2011 Nov 8;29(48):8771; author reply 8772. doi: 10.1016/j.vaccine.2011.08.046. Epub 2011 Aug 22. Vaccine. 2011. PMID: 21864628 No abstract available.
Comment on
-
Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine.Vaccine. 2011 May 9;29(20):3628-32. doi: 10.1016/j.vaccine.2011.03.018. Epub 2011 Mar 22. Vaccine. 2011. PMID: 21435407
References
-
- Tseng HF, Smith N, Sy LS, Jacobsen SJ. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine. 2011;29(20):3628–32. - PubMed
-
- Centers for Disease Control and Prevention. Recommended adult immunization schedule – United States, 2011. MMWR. 2011;60(4):1–4. - PubMed
-
- Zostavax. prescribing information [package insert] 2009:6. Section 7.1.
-
- High KP. Overcoming barriers to adult immunization. J Am Osteopath Assoc. 2009 Jun;109(6 Suppl 2):S25–8. - PubMed
-
- Lieu TA, Ortega-Sanchez I, Ray GT, et al. Community and patient values for preventing herpes zoster. Pharmacoeconomics. 2008;26(3):235–49. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical